We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

By LabMedica International staff writers
Posted on 06 May 2025

Speed and accuracy are essential when diagnosing diseases. More...

Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures, often resulting in several days of waiting before targeted treatment can begin. Researchers have now developed a groundbreaking method that can identify bacteria with unprecedented speed, reducing the waiting time from several days to just a few minutes.

The innovative approach, developed by researchers at Technical University of Munich (TUM, Munich, Germany) and Imperial College London (London, UK) uses mass spectrometry to detect specific metabolic products of bacteria directly from tissue and stool samples. Central to this process is a database that currently includes 232 medically relevant bacterial species and their associated metabolic products. From this database, biomarkers are extracted to allow for the direct identification of specific bacteria.

The new method is capable of identifying bacteria responsible for a variety of serious conditions, including stomach cancer, pneumonia, meningitis, preterm birth, gonorrhea, and sepsis. To ensure that this method becomes a regular tool in clinical settings, the biomarker database needs to be expanded. The researchers note that over 1,400 bacterial pathogens are known, and their specific metabolic products need to be identified and added to the database. The team also sees significant potential for this method in personalized medicine, where treatments can be tailored precisely to individual patients based on the specific bacteria detected.

"Our innovative approach is not to look directly for the pathogenic bacteria, but only for their metabolic products. This allows us to detect them indirectly, but much more quickly," said first author Wei Chen.

"This is one of the most important future topics in biotechnology and medicine. Targeted interventions can dramatically improve the chances of successful treatment. As analysts, we develop modern tools and methods for doctors to do this," added Prof. Nicole Strittmatter.

Related Links:
TUM 
Imperial College London 


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.